TrialCancer science2025

Phase II study of perioperative camrelizumab and XELOX for locally advanced gastric or gastroesophageal junction adenocarcinoma.

Jiaxing He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.